317 related articles for article (PubMed ID: 18042049)
1. Importance of intensive lipid lowering in acute coronary syndrome and percutaneous coronary intervention.
Kumar A; Cannon CP
J Interv Cardiol; 2007 Dec; 20(6):447-57. PubMed ID: 18042049
[TBL] [Abstract][Full Text] [Related]
2. Effect of intensive statin therapy on clinical outcomes among patients undergoing percutaneous coronary intervention for acute coronary syndrome. PCI-PROVE IT: A PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) Substudy.
Gibson CM; Pride YB; Hochberg CP; Sloan S; Sabatine MS; Cannon CP;
J Am Coll Cardiol; 2009 Dec; 54(24):2290-5. PubMed ID: 19958964
[TBL] [Abstract][Full Text] [Related]
3. Effect of intensive lipid-lowering therapy on mortality after acute coronary syndrome (a patient-level analysis of the Aggrastat to Zocor and Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 trials).
Murphy SA; Cannon CP; Wiviott SD; de Lemos JA; Blazing MA; McCabe CH; Califf RM; Braunwald E
Am J Cardiol; 2007 Oct; 100(7):1047-51. PubMed ID: 17884359
[TBL] [Abstract][Full Text] [Related]
4. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial.
Murphy SA; Cannon CP; Wiviott SD; McCabe CH; Braunwald E
J Am Coll Cardiol; 2009 Dec; 54(25):2358-62. PubMed ID: 20082923
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of China intensive lipid lowering with statins in acute coronary syndrome: the CHILLAS study.
Zhao SP; Peng DQ; Yu BL; Huo Y;
Am Heart J; 2009 Oct; 158(4):509-512.e1. PubMed ID: 19781407
[TBL] [Abstract][Full Text] [Related]
6. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis.
Middleton A; Binbrek AS; Fonseca FA; Wilpshaar W; Watkins C; Strandberg TE
Curr Med Res Opin; 2006 Jun; 22(6):1181-91. PubMed ID: 16846551
[TBL] [Abstract][Full Text] [Related]
7. Impact of the pravastatin or atorvastatin evaluation and infection therapy-thrombolysis in myocardial infarction 22/Reversal of Atherosclerosis with Aggressive Lipid Lowering trials on trends in intensive versus moderate statin therapy in Ontario, Canada.
Austin PC; Mamdani MM
Circulation; 2005 Aug; 112(9):1296-300. PubMed ID: 16116054
[TBL] [Abstract][Full Text] [Related]
8. Prognostic utility of apoB/AI, total cholesterol/HDL, non-HDL cholesterol, or hs-CRP as predictors of clinical risk in patients receiving statin therapy after acute coronary syndromes: results from PROVE IT-TIMI 22.
Ray KK; Cannon CP; Cairns R; Morrow DA; Ridker PM; Braunwald E
Arterioscler Thromb Vasc Biol; 2009 Mar; 29(3):424-30. PubMed ID: 19122170
[TBL] [Abstract][Full Text] [Related]
9. A clinical focus on statins.
Auer J; Eber B
Curr Opin Investig Drugs; 2001 Mar; 2(3):382-8. PubMed ID: 11575709
[TBL] [Abstract][Full Text] [Related]
10. [Early initiation of statin therapy in patients with acute myocardial infarction after successful percutaneous coronary intervention].
Katayama N; Nakao K; Horiuchi K; Ogawa H; Honda T
J Cardiol; 2004 Oct; 44(4):131-40. PubMed ID: 15532243
[TBL] [Abstract][Full Text] [Related]
11. The beneficial effect of high loading dose of rosuvastatin before percutaneous coronary intervention in patients with acute coronary syndrome.
Yun KH; Jeong MH; Oh SK; Rhee SJ; Park EM; Lee EM; Yoo NJ; Kim NH; Ahn YK; Jeong JW
Int J Cardiol; 2009 Nov; 137(3):246-51. PubMed ID: 18706705
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy of rosuvastatin versus atorvastatin in reducing apolipoprotein B/apolipoprotein A-1 ratio in patients with acute coronary syndrome: results of the CENTAURUS study.
Lablanche JM; Leone A; Merkely B; Morais J; Alonso J; Santini M; Eha J; Demil N; Licour M; Tardif JC;
Arch Cardiovasc Dis; 2010 Mar; 103(3):160-9. PubMed ID: 20417447
[TBL] [Abstract][Full Text] [Related]
13. Lipid levels after acute coronary syndromes.
Pitt B; Loscalzo J; Ycas J; Raichlen JS
J Am Coll Cardiol; 2008 Apr; 51(15):1440-5. PubMed ID: 18402897
[TBL] [Abstract][Full Text] [Related]
14. Early time to benefit with intensive statin treatment: could it be the pleiotropic effects?
Ray KK; Cannon CP
Am J Cardiol; 2005 Sep; 96(5A):54F-60F. PubMed ID: 16126024
[TBL] [Abstract][Full Text] [Related]
15. Impact of statin therapy on coronary intervention for non-ST elevation acute coronary syndrome with decreased low-density lipoprotein cholesterol.
Hara H; Nakamura M; Yokouchi I; Kimura K; Nemoto N; Ito S; Ono T; Shiba M; Wada M; Tsuji T; Komatsu H; Iijima R; Nakajima R; Yamamoto M; Yamamoto M; Yoshitama T; Takagi T; Hara H; Sugi K
J Cardiol; 2007 Mar; 49(3):115-23. PubMed ID: 17444137
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of intensive statin therapy in the elderly.
Maroo BP; Lavie CJ; Milani RV
Am J Geriatr Cardiol; 2008; 17(2):92-100. PubMed ID: 18326948
[TBL] [Abstract][Full Text] [Related]
17. Beyond lipid lowering: What have we learned about the benefits of statins from the acute coronary syndromes trials?
Ray KK; Cannon CP; Ganz P
Am J Cardiol; 2006 Dec; 98(11A):18P-25P. PubMed ID: 17126675
[TBL] [Abstract][Full Text] [Related]
18. [Coronary disease prevention: only the inhibition of inflammation is important. Why lower lipids, too?].
Sudhop T; von Bergmann K
MMW Fortschr Med; 2003 May; 145(21):19. PubMed ID: 12845862
[No Abstract] [Full Text] [Related]
19. Baseline low-density lipoprotein cholesterol is an important predictor of the benefit of intensive lipid-lowering therapy: a PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) analysis.
Giraldez RR; Giugliano RP; Mohanavelu S; Murphy SA; McCabe CH; Cannon CP; Braunwald E
J Am Coll Cardiol; 2008 Sep; 52(11):914-20. PubMed ID: 18772061
[TBL] [Abstract][Full Text] [Related]
20. Are statins created equal? Evidence from randomized trials of pravastatin, simvastatin, and atorvastatin for cardiovascular disease prevention.
Zhou Z; Rahme E; Pilote L
Am Heart J; 2006 Feb; 151(2):273-81. PubMed ID: 16442888
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
